Astrazeneca Plc · LSE:AZN
Astrazeneca — Merger or Acquisition (April 2014)
23 slides from Astrazeneca's merger presentation, Apr 28, 2014
Slide 1: Pfizer Announcement Related to AstraZeneca
Exhibit 99.6 Pfizer Announcement Related to AstraZeneca April 28, 2014
Slide 2: Introduction
Introduction Chuck Triano Senior Vice President, Investor Relations
Slide 3: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are
Slide 4: Agenda
Agenda Potential Offer Background & Summary Pfizer Overview Potential Pfizer + AstraZeneca Combination Next Steps 4
Slide 5: Prepared Remarks
Prepared Remarks Ian Read Chairman and Chief Executive Officer
Slide 6: Potential Offer Background & Summary
Potential Offer Background & Summary
Slide 7: Background
Background Pfizer previously submitted a preliminary, non-binding indication of interest to AstraZeneca’s Board In January, Pfizer’s proposal included a combination of cash and shares which represented an indicative value of £46.61 ($76.62) per share (based on Pfizer’s closing share price of $30.52
Slide 8: Why This Is The Right Time
Why This Is The Right Time Pfizer has strong standalone operating and financial momentum New commercial structure driving strong operating performance, financial focus and a clear vision towards value creation Potential combination with AstraZeneca aligns with Pfizer’s operating structure in both th
Slide 9: Why Potential Offer Should Be Highly Compelling for AstraZeneca Shareholders
Why Potential Offer Should Be Highly Compelling for AstraZeneca Shareholders Potential to realize a significant premium Significant premium to the undisturbed AstraZeneca share price as of April 17, 2014 Substantial cash payment Opportunity to share in Pfizer value upside over medium / long-term Via
Slide 10: Why the Potential Combination Would Bring Benefits to Pfizer
Why the Potential Combination Would Bring Benefits to Pfizer Would enable acceleration of our business strategy and strengthen competitive position Would enhance global offerings for Innovative businesses while also creating a stronger research platform in key areas and increasing new product launch
Slide 11: Pfizer Overview
eee Pfizer Overview
Slide 12: Pfizer Profile
Pfizer Profile manufacturing countries Revenue in 2013 products with sales >$1 sites worldwide (as of in which Pfizer billion in 2013 4Q’13) sells products colleagues around the R&D partner institutions of Cash Flow from to shareholders through globe (as of 3/31/2014) Operations in 2013 dividends an
Slide 13: From Advil to Zithromax…
From Advil to Zithromax… Our Medicines, Vaccines and Consumer Health Products Help Billions of Patients Every Year 13
Slide 14: New Commercial Structure
New Commercial Structure Announced internal separation of our commercial and management structure into three businesses effective at the start of fiscal 2014 Global Innovative Pharma Vaccines, Oncology and Global Established Pharma Consumer Healthcare Geno Germano, Group President Albert Bourla, Gro
Slide 15: Proven Track Record of Strong Integration
Proven Track Record of Strong Integration Long history of strong integration of transformational business combinations Prior examples of Pharmacia and Wyeth Wyeth example of strong cost rationalization experience Wyeth-related synergy targets of $4B from the combined companies Exceeded Wyeth synergy
Slide 16: Potential Pfizer + AstraZeneca Combination
Potential Pfizer + AstraZeneca Combination
Slide 17: Strategic Rationale for Combination of Pfizer and AstraZeneca
Strategic Rationale for Combination of Pfizer and AstraZeneca Expect positive growth driven by leading Innovative businesses operating at a global scale Complementary strategic fit across multiple key therapeutic areas with enhanced global offerings Innovative Businesses Steady stream of potential n
Slide 18: Strategic Rationale
Strategic Rationale Complementary Innovative Portfolios Global Innovative Pharma Vaccines, Oncology, Consumer (GIP) Health (VOC) Complementary attractive Pfizer AstraZeneca Pfizer AstraZeneca portfolios across multiple key therapeutic areas Inflammation Xeljanz Lesinurad Vaccines Prevnar FluMist & I
Slide 19: Strategic Rationale
Strategic Rationale Complementary Innovative Pipelines, Strengthens Key TAs Global Innovative Pharma Vaccines, Oncology, Consumer Strong combined pipeline (GIP) Health (VOC) driving potential innovative growth Pfizer AstraZeneca Pfizer AstraZeneca Inflammation PD-0360324 Brodalumab Vaccines MnB vacc
Slide 20: Strategic Rationale
Strategic Rationale Complementary Established Portfolios Global Established Products Scale and Breadth to Maximize Potential (GEP) of Established Portfolios Pfizer AstraZeneca Increased critical mass for market access and cost Primary & Lipitor, Celebrex, Symbicort efficiencies Specialty Viagra (ex-
Slide 21: Next Steps
Next Steps
Slide 22: Next Steps
Next Steps Pfizer would like to negotiate a possible combination on a friendly basis Hope to continue discussions with AstraZeneca Begin engagement with other key stakeholders of both companies UK Takeover Code provides 28 day window after today’s announcement Pfizer may either announce a firm offer
Slide 23: Q&A Session
Q&A Session April 28, 2014